Intravitreally Administered Soluble VEGF Receptor-1 Variant Tested as a Potential Gene Therapeutic for Diabetic Retinopathy

Figure 5

rAAV2-sVEGFRv-1 protects against retinal cell layer thinning. The effect of the therapeutic virus vector upon the cell layers of the mouse retinas suggests that rAAV2-sVEGFRv-1 has neuroprotective qualities. This can be seen in the changing thicknesses of the retinal cell layers (a), visualized 5 months post intravitreal injection and calculated as a ratio relative to normal control mice () (b), with the effect on the inner nuclear layer being noted specifically () (c). Scale bar: 50 μm; vs. sham.

(a)

(b)

(c)